

Minutes
Drug Utilization Review Board Meeting
 DATE: December 10, 2025



Meeting Purpose: Quarterly Drug Utilization Board Meeting
 Meeting opened at 6:00 p.m. by Rebeka Rice, Pharm.D, R.Ph.

The meeting was conducted under Massachusetts Public Meeting Law requirements.

Attendance: Diane Bruessow, DMS, PA-C, CPXP, DFAAPA; Colleen Labelle, MSN, RN-BC, CARN; Lori Lewicki, RPh; Mirembe Reed, PharmD.; Rebeka Rice, Pharm.D, R.Ph.; Zenhi Stavre, MD; Christy Stine, MD, PhD

Absent: Mehmet Furkan Burbak, MD; Timothy Fensky, RPh; Jaqueline Gagnon, RPh; Mathew Moll, MD, MPH; Bavesh Shah, PharmD; Laura Spring, MD

Agenda Items:

- Welcome and Introductory Remarks
- Clinical Update: Diabetes and Obesity Management
- Clinical Update: Hereditary Angioedema Management
- Multiple Sclerosis Quality Assurance Analysis
- MHDL Update
- MassHealth Update
- Cerebral Stimulants and ADHD Treatments Quality Assurance Analysis
- Open Forum

Agenda Item	Discussion	Conclusions/Follow-up
Minutes	Motion to approve the minutes for September 2025 was made by Bruessow and was seconded by Stine.	Follow-up Minutes are approved.
Clinical Update: Diabetes and Obesity Management	<u>Clinical Update: Diabetes and Obesity Management by Dr. Kaelyn Boss</u> This was an overview of updates to management in glucagon-like peptide-1 (GLP-1) agents in the management of diabetes and obesity.	Follow-up Informational/Advisory
Action	Discussion <ul style="list-style-type: none"> • Reviewed MassHealth coverage of anti-obesity medications 	Conclusion

Agenda Item	Discussion	Conclusions/Follow-up
	<ul style="list-style-type: none"> • Highlighted use of anti-obesity medications • Discussed new FDA-approved indications GLP-1 agents • Summarized expected changes to MassHealth management <p>Conclusions</p> <ul style="list-style-type: none"> • MassHealth covers GLP-1 agents for multiple indications, including obesity/overweight, since January 2024. • MassHealth manages this class with PA and preferred drug designation. • Recent clinical changes within the class include expanding use of Wegovy® (semaglutide) to MASH and supporting literature in Saxenda (liraglutide) in children six to 12 years. 	<p>The board reviewed and accepted the presentation.</p>

Agenda Item	Discussion	Conclusions/Follow-up
<p>Clinical Update: Hereditary Angioedema (HAE) Management</p>	<p><u>Clinical Update: Hereditary Angioedema Management by Dr. Mark Tesell</u> This update of the current medical literature provided a brief overview of newly approved agents in this disease state.</p>	<p><u>Follow-up</u> Informational/Advisory</p>
<p>Action</p>	<p>Discussion</p> <ul style="list-style-type: none"> • Provided background information on HAE • Summarized current consensus guideline recommendations • Reviewed current class management and findings from a quality assurance analysis of HAE agents • Evaluated three new medications that were indicated for the treatment or prophylaxis of HAE • Discussed and recommended changes to current MassHealth management of this class and management of new HAE agents <p>Conclusions</p>	<p><u>Conclusion</u> The board reviewed and accepted the presentation.</p>

Agenda Item	Discussion	Conclusions/Follow-up
	<ul style="list-style-type: none"> • Current consensus guidelines support the use of all FDA-approved acute and prophylactic medications as first-line treatment options for HAE. • There are minimal PA requests for and utilization of agents in this class, but many agents are still associated with a high cost to MassHealth. • Andembry® (garadacimab-gxii) and Dawnzera® (donidalorsen) were approved by the FDA for HAE prophylaxis, and each product offers unique advantages against their comparators. • Ekterly® (sebetralstat) is the first oral medication approved by the FDA for the treatment of acute HAE attacks. • Changes to MassHealth management of this class include the following. <ul style="list-style-type: none"> ○ Acute HAE agents will be available without PA within a quantity limit sufficient for the treatment of two HAE attacks per 30 days. ○ All three new HAE medications reviewed will require prior authorization (PA). 	

Agenda Item	Discussion	Conclusions/Follow-up
Multiple Sclerosis (MS) QA	<p><u>Multiple Sclerosis QA Analysis by Dr. Andrew Coelho</u> This analysis was of an evaluation of current medical literature and provided a brief overview of new guideline recommendations in this disease state.</p>	<p><u>Follow-up</u> Informational/Advisory</p>
Action	<p>Discussion</p> <ul style="list-style-type: none"> • Provided a brief overview of MS • Reviewed FDA-approved disease-modifying therapy and current MassHealth management • Assessed use and PA requests • Discussed recent updates in clinical literature • Presented QA recommendations <p>Conclusions</p> <ul style="list-style-type: none"> • There are/have been no notable clinical updates to the MS agents class. <ul style="list-style-type: none"> ○ Limited guidance available to support changes in other management ○ Evaluating changes in cost to be continued • There have been no significant changes in use or PA requests since the last review. • MassHealth will continue to monitor the extensive pipeline, including eight agents in phase III trials. 	<p><u>Conclusion</u> The board reviewed and accepted the presentation.</p>

Agenda Item	Discussion	Conclusions/Follow-up
	<ul style="list-style-type: none"> Continued evaluation of clinical literature and guidelines will guide future updates. 	

Agenda Item	Discussion	Conclusions/Follow-up
MassHealth Drug List (MHDL) Update	<u>MHDL Update by Dr. Christin Maesto</u> MHDL overview included new additions, changes in PA status, and related attachment updates to be implemented with a recent publication rollout.	<u>Follow-up</u> Informational/Advisory
Action	Discussion <ul style="list-style-type: none"> Effective January 5, 2025: <ul style="list-style-type: none"> There were 20 additions to the MHDL. There were nine changes in PA status. There were several changes to Coverage Status; Coverage Status for Brand Name Preferred Over Generic List; New FDA- "A"-rated Generics; 90-day Initiative; MassHealth Supplemental Rebate/Preferred Drug List; and MassHealth Preferred Non-Drug Product List and Miscellaneous Updates. 	<u>Conclusion</u> The board reviewed and accepted the presentation.

Agenda Item	Discussion	Conclusions/Follow-up
MassHealth Update	<u>MassHealth Update by Dr. Kimberly Lenz</u> MassHealth update is a summary of recent developments in MassHealth in the context of pharmacy, managed care, or public health.	<u>Follow-up</u> Informational/Advisory
Action	Discussion <ul style="list-style-type: none"> Reviewed current clinical program initiatives Provided direct negotiation status update Discussed operational updates 	<u>Conclusion</u> The board reviewed and accepted the presentation.

Agenda Item	Discussion	Conclusions/Follow-up
Cerebral Stimulants and Attention Deficit Hyperactivity Disorder (ADHD) Treatments QA Analysis	<p><u>Cerebral Stimulants and ADHD Treatments QA Analysis by Dr. Amy Dionne</u></p> <p>This was an overview of an evaluation of current medical literature and provided a brief analysis of new guideline recommendations in this disease state.</p>	<p><u>Follow-up</u> Informational/Advisory</p>
<p>Action</p>	<p>Discussion</p> <ul style="list-style-type: none"> • Reviewed guidelines for treatment of ADHD • Summarized class management strategy • Discussed trends in utilization • Outlined PA criteria • Reviewed PA request metrics <p>Conclusions</p> <ul style="list-style-type: none"> • Utilization is driven by use of preferred agents. • PA submissions have been distributed equally between children and adults. • PA criteria continued to remain clinically appropriate. 	<p><u>Conclusion</u> The board reviewed and accepted the presentation</p>

Agenda Item	Discussion	Conclusions/Follow-up
<p>Open Forum</p>	<p><u>Open Forum</u></p>	<p><u>Follow-up</u> Informational/Advisory</p>

Meeting adjourned at 8:00 p.m.

Respectfully submitted by Mylissa Price

Date: _____